Who are Tildrakizumab Prefilled Syringe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ilumya Injectable Product, Ustekinumab Injection, Guselkumab Dose 1, Stelara (ustekinumab), Guselkumab Subcutaneous, risankizumab SC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tildrakizumab-prefilled-syringe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Tildrakizumab Prefilled Syringe — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tildrakizumab Prefilled Syringe (Tildrakizumab Prefilled Syringe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-23 inhibitor (monoclonal antibody). Area: Immunology / Dermatology.

marketed IL-23 inhibitor (monoclonal antibody) IL-23 (interleukin-23), p19 subunit Immunology / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Tildrakizumab Prefilled Syringe (Tildrakizumab Prefilled Syringe) — Brigham and Women's Hospital. Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tildrakizumab Prefilled Syringe TARGET	Tildrakizumab Prefilled Syringe	Brigham and Women's Hospital	marketed	IL-23 inhibitor (monoclonal antibody)	IL-23 (interleukin-23), p19 subunit
Ilumya Injectable Product	Ilumya Injectable Product	Psoriasis Treatment Center of Central New Jersey	marketed	IL-23 inhibitor (monoclonal antibody)	IL-23 p19 subunit
Ustekinumab Injection	Ustekinumab Injection	National Medical Research Center for Children's Health, Russian Federation	marketed	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12/IL-23 p40 subunit
Guselkumab Dose 1	Guselkumab Dose 1	Janssen Research & Development, LLC	phase 3	IL-23 inhibitor (monoclonal antibody)	IL-23 (p19 subunit)
Stelara (ustekinumab)	Stelara (ustekinumab)	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12 p40 subunit / IL-23 p40 subunit
Guselkumab Subcutaneous	Guselkumab Subcutaneous	Janssen Research & Development, LLC	phase 3	IL-23 inhibitor (monoclonal antibody)	IL-23 (p19 subunit)
risankizumab SC	risankizumab SC	AbbVie	phase 3	IL-23 inhibitor (monoclonal antibody)	IL-23 p19 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-23 inhibitor (monoclonal antibody) class)

Janssen Research & Development, LLC · 2 drugs in this class
AbbVie · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
Psoriasis Treatment Center of Central New Jersey · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tildrakizumab Prefilled Syringe — Competitive Intelligence Brief. https://druglandscape.com/ci/tildrakizumab-prefilled-syringe. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab